Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23398359 | 1.00 | TLR8 (0.44) | TLR8TSHRHTR2AGPR84SRC | |
| SCHEMBL207523 | 0.81 | HTR2A (0.46) | TLR8TSHRHTR2AGPR84SRC | |
| SCHEMBL1971171 | 0.81 | TYR (0.44) | TLR8TSHRHTR2AMAPTTYR | |
| SCHEMBL1969918 | 0.81 | TYR (0.44) | TLR8TSHRHTR2AMAPTTYR | |
| SCHEMBL1971686 | 0.81 | TYR (0.44) | TLR8TSHRHTR2AMAPTTYR | |
| SCHEMBL2018932 | 0.81 | HTR2A (0.46) | TLR8TSHRHTR2AGPR84SRC | |
| SCHEMBL12798389 | 0.81 | HTR2A (0.46) | TLR8TSHRHTR2AGPR84SRC | |
| SCHEMBL10345219 | 0.81 | HTR2A (0.46) | TLR8TSHRHTR2AGPR84SRC | |
| SCHEMBL5377545 | 0.81 | MAPT (0.49) | TLR8TSHRHTR2AGPR84SRC | |
| SCHEMBL27796305 | 0.81 | HTR2A (0.46) | TLR8TSHRHTR2AGPR84SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387369-A1 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2022-12-08 | — | — | US | claimed |
| EP-4065095-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2022-10-05 | — | — | EP | claimed |
| WO-2021105435-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2021-06-03 | — | — | WO | claimed |
| EP-3827816-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2021-06-02 | — | — | EP | claimed |
| US-20220387369-A1 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2022-12-08 | — | — | US | disclosed |
| EP-4065095-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105435-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2021-06-03 | — | — | WO | disclosed |
| EP-3827816-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2021-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387369-A1 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | SLC25A1, SLC19A2, SLC25A21 | TLR8 775/4885TSHR 1203/4885HTR2A 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.